1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Life Science Research Services Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Life Science Research Services Market, by Service Type
8.1.1. Drug Discovery & Target Validation Services
8.1.1.1. Market Revenue and Forecast
8.1.2. Preclinical Research Services
8.1.2.1. Market Revenue and Forecast
8.1.3. Clinical Research Services
8.1.3.1. Market Revenue and Forecast
8.1.4. Bioanalytical & Laboratory Testing Services
8.1.4.1. Market Revenue and Forecast
8.1.5. Genomics & Proteomics Services
8.1.5.1. Market Revenue and Forecast
8.1.6. Cell-Based Assays & In Vitro Testing
8.1.6.1. Market Revenue and Forecast
8.1.7. Toxicology Testing Services
8.1.7.1. Market Revenue and Forecast
9.1. Life Science Research Services Market, by Therapeutic Area
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast
9.1.2. Cardiovascular
9.1.2.1. Market Revenue and Forecast
9.1.3. Neurology
9.1.3.1. Market Revenue and Forecast
9.1.4. Immunology
9.1.4.1. Market Revenue and Forecast
9.1.5. Metabolic Disorders
9.1.5.1. Market Revenue and Forecast
9.1.5. Infectious Diseases
9.1.5.1. Market Revenue and Forecast
9.1.5. Rare Diseases
9.1.5.1. Market Revenue and Forecast
10.1. Life Science Research Services Market, by End-User
10.1.1. Pharmaceutical Companies
10.1.1.1. Market Revenue and Forecast
10.1.2. Biotechnology Companies
10.1.2.1. Market Revenue and Forecast
10.1.3. Medical Device Companies
10.1.3.1. Market Revenue and Forecast
10.1.4. Academic & Research Institutes
10.1.4.1. Market Revenue and Forecast
10.1.5. Government & Public Health Organizations
10.1.5.1. Market Revenue and Forecast
11.1. Life Science Research Services Market, by Technology Platform
11.1.1. High-Throughput Screening (HTS)
11.1.1.1. Market Revenue and Forecast
11.1.2. Next-Generation Sequencing (NGS)
11.1.2.1. Market Revenue and Forecast
11.1.3. Bioinformatics & Data Analytics
11.1.3.1. Market Revenue and Forecast
11.1.4. Cell Imaging & Flow Cytometry
11.1.4.1. Market Revenue and Forecast
11.1.5. AI-Driven Drug Discovery Tools
11.1.5.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Service Type
12.1.2. Market Revenue and Forecast, by Therapeutic Area
12.1.3. Market Revenue and Forecast, by End-User
12.1.4. Market Revenue and Forecast, by Technology Platform
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Service Type
12.1.5.2. Market Revenue and Forecast, by Therapeutic Area
12.1.5.3. Market Revenue and Forecast, by End-User
12.1.5.4. Market Revenue and Forecast, by Technology Platform
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Service Type
12.1.6.2. Market Revenue and Forecast, by Therapeutic Area
12.1.6.3. Market Revenue and Forecast, by End-User
12.1.6.4. Market Revenue and Forecast, by Technology Platform
12.2. Europe
12.2.1. Market Revenue and Forecast, by Service Type
12.2.2. Market Revenue and Forecast, by Therapeutic Area
12.2.3. Market Revenue and Forecast, by End-User
12.2.4. Market Revenue and Forecast, by Technology Platform
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Service Type
12.2.5.2. Market Revenue and Forecast, by Therapeutic Area
12.2.5.3. Market Revenue and Forecast, by End-User
12.2.5.4. Market Revenue and Forecast, by Technology Platform
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Service Type
12.2.6.2. Market Revenue and Forecast, by Therapeutic Area
12.2.6.3. Market Revenue and Forecast, by End-User
12.2.6.4. Market Revenue and Forecast, by Technology Platform
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Service Type
12.2.7.2. Market Revenue and Forecast, by Therapeutic Area
12.2.7.3. Market Revenue and Forecast, by End-User
12.2.7.4. Market Revenue and Forecast, by Technology Platform
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Service Type
12.2.8.2. Market Revenue and Forecast, by Therapeutic Area
12.2.8.3. Market Revenue and Forecast, by End-User
12.2.8.4. Market Revenue and Forecast, by Technology Platform
12.3. APAC
12.3.1. Market Revenue and Forecast, by Service Type
12.3.2. Market Revenue and Forecast, by Therapeutic Area
12.3.3. Market Revenue and Forecast, by End-User
12.3.4. Market Revenue and Forecast, by Technology Platform
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Service Type
12.3.5.2. Market Revenue and Forecast, by Therapeutic Area
12.3.5.3. Market Revenue and Forecast, by End-User
12.3.5.4. Market Revenue and Forecast, by Technology Platform
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Service Type
12.3.6.2. Market Revenue and Forecast, by Therapeutic Area
12.3.6.3. Market Revenue and Forecast, by End-User
12.3.6.4. Market Revenue and Forecast, by Technology Platform
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Service Type
12.3.7.2. Market Revenue and Forecast, by Therapeutic Area
12.3.7.3. Market Revenue and Forecast, by End-User
12.3.7.4. Market Revenue and Forecast, by Technology Platform
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Service Type
12.3.8.2. Market Revenue and Forecast, by Therapeutic Area
12.3.8.3. Market Revenue and Forecast, by End-User
12.3.8.4. Market Revenue and Forecast, by Technology Platform
12.4. MEA
12.4.1. Market Revenue and Forecast, by Service Type
12.4.2. Market Revenue and Forecast, by Therapeutic Area
12.4.3. Market Revenue and Forecast, by End-User
12.4.4. Market Revenue and Forecast, by Technology Platform
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Service Type
12.4.5.2. Market Revenue and Forecast, by Therapeutic Area
12.4.5.3. Market Revenue and Forecast, by End-User
12.4.5.4. Market Revenue and Forecast, by Technology Platform
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Service Type
12.4.6.2. Market Revenue and Forecast, by Therapeutic Area
12.4.6.3. Market Revenue and Forecast, by End-User
12.4.6.4. Market Revenue and Forecast, by Technology Platform
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Service Type
12.4.7.2. Market Revenue and Forecast, by Therapeutic Area
12.4.7.3. Market Revenue and Forecast, by End-User
12.4.7.4. Market Revenue and Forecast, by Technology Platform
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Service Type
12.4.8.2. Market Revenue and Forecast, by Therapeutic Area
12.4.8.3. Market Revenue and Forecast, by End-User
12.4.8.4. Market Revenue and Forecast, by Technology Platform
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Service Type
12.5.2. Market Revenue and Forecast, by Therapeutic Area
12.5.3. Market Revenue and Forecast, by End-User
12.5.4. Market Revenue and Forecast, by Technology Platform
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Service Type
12.5.5.2. Market Revenue and Forecast, by Therapeutic Area
12.5.5.3. Market Revenue and Forecast, by End-User
12.5.5.4. Market Revenue and Forecast, by Technology Platform
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Service Type
12.5.6.2. Market Revenue and Forecast, by Therapeutic Area
12.5.6.3. Market Revenue and Forecast, by End-User
12.5.6.4. Market Revenue and Forecast, by Technology Platform
13.1. Thermo Fisher Scientific
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Danaher Corporation
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Merck KGaA
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Agilent Technologies
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. F. Hoffmann-La Roche Ltd.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Becton, Dickinson and Company
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Bio-Rad Laboratories
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Qiagen N.V.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Bruker Corporation
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
